Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？
Background
Pulmonary embolism (PE) represents a major cause of morbidity and mortality in patients with cancer due to their heightened prothrombotic state. Proper anticoagulation is critical to prevent recurrent venous thromboembolism (VTE), but the optimal duration for anticoagulation in cancer-associated acute low-risk PE remains unclear. Extending anticoagulation might reduce recurrent thrombotic events but raises concerns about increased bleeding, especially in a vulnerable oncologic population. This clinical equipoise underpins the ONCO PE trial conducted in Japan, evaluating rivaroxaban treatment duration in this patient group.
Study Design
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.